Quantumzyme Corp. (OTC: QTZM), a biotransformation company specializing in sustainable pharmaceutical manufacturing, issued a corporate update on January 26, 2026, detailing its 2025 achievements and strategic priorities for 2026. The company also announced plans to change its name to Quantum Genesis AI Corp., subject to regulatory approvals, signaling a greater emphasis on artificial intelligence and computational research in enzyme development.
During 2025, Quantumzyme focused on foundational research and development in enzyme engineering and biocatalytic processes for pharmaceutical and specialty chemical applications. The company advanced its regulatory reporting, published U.S. and international patent applications for enzymatic processes, and updated its corporate communications to better articulate its business focus. These efforts remain in the research and evaluation stage, with no assurance of commercial success.
A key development in 2025 was the expansion of artificial intelligence and computational research. Quantumzyme began integrating machine learning and computational modeling into its enzyme discovery and structure-function analysis, aiming to improve experimental design and data analysis efficiency. These AI initiatives are exploratory and intended for internal decision support, not commercial software development. The company believes this integration may guide future research, but it faces technical and financial limitations.
In late 2025, the board approved a proposal to change the legal name to Quantum Genesis AI Corp., reflecting the intensified focus on computational and data-driven approaches. The company has submitted documentation for the name and trading symbol change, which requires FINRA approval and is expected to be completed in the first quarter of 2026, though timing is uncertain.
For 2026, Quantumzyme outlined several strategic priorities. These include advancing enzyme candidates and biocatalytic pathways through internal testing and feasibility assessment, continuing refinement of computational modeling and AI tools, exploring potential collaborations with pharmaceutical and chemical companies, increasing market visibility through scientific forums and investor communications, and assessing long-term corporate objectives such as reporting status and capital planning. The company cautions that these objectives are subject to risks including technical challenges, capital availability, and market conditions.
Quantumzyme Corp. is based in San Diego, California, and focuses on sustainable enzyme-based solutions for pharmaceutical manufacturing. The company applies quantum mechanics, molecular modeling, AI-driven simulations, and computational enzyme engineering to develop biocatalysts that enhance efficiency and reduce waste. More information is available at www.quantumzymecorp.com and the company’s profile at www.otcmarkets.com/stock/QTZM.
This press release contains forward-looking statements subject to risks and uncertainties. Quantumzyme undertakes no obligation to update these statements. Investors should conduct their own due diligence before making decisions.
